Wednesday, July 30, 2008

Yale Researchers Find New Trigger For Autoimmune Diseases

Yale Researchers Find New Trigger For Autoimmune Diseases
Medical News Today Tue, 29 Jul 2008 3:11 AM PDT
Yale University researchers have discovered a new way that autoimmune diseases like multiple sclerosis (MS) can be triggered, they reported Monday in the journal Proceedings of the National Academy of Sciences. Scientists have long known the molecule TGF-Beta (transforming growth factor Beta) plays a pivotal role in preventing T cells from launching an attack on the body's own tissues.



Successes, failures shape a candidate
Columbia Daily Tribune - Columbia,MO,USA
He was diagnosed with multiple sclerosis in 2003 and eventually saw his deductible on his prescriptions jump precipitously. He noted a similar program in ...
See all stories on this topic



The image “http://z.about.com/h/hp/logo.gif” cannot be displayed, because it contains errors.Multiple Sclerosis
The image “http://z.about.com/h/g/25262.jpg” cannot be displayed, because it contains errors.
from Julie Stachowiak, Ph.D.
I kind of feel like this newsletter is a little more "instructive" and maybe not as supportive as I would like to be. However, I had these specific things on my mind and thought some of this information might come in handy - especially after talking to a friend that just found out about a "blessed surprise" (aka unplanned pregnancy), due to taking antibiotics while she was relying on birth control pills. It's very important for those of us on certain meds to plan our pregnancies in a way that does not expose our babies to medications that might be dangerous to them.
On a different note, I also hope to give some of you a measure of comfort with my relapse checklist, and also give you my sympathies (and encouragement) if your friends are letting you know how poorly you seem to be doing in the heat. Take care of yourselves.


Some Medications Interfere with Birth Control

It is especially important to carefully research every drug, herbal supplement and over-the-counter medication that you might take if you are using hormonally based contraception. While your first thoughts may be about the birth control pill, this also includes patches, rings, implants, injections and intrauterine devices (IUDs). As it turns out, many drugs make these contraception methods less effective, which could lead to unwanted pregnancies. Read the full article: Some Medications Interfere with Birth Control



How Do I Know If I'm Having a Relapse?

With all of the MS-related heat intolerance that we are all suffering through, it is pretty hard to tell if we are in the middle of a relapse, or just out of whack because of the weather. Hopefully, this list will help you figure out what is going on. Of course, the only way to really know is to get an MRI... Read the full article: How Do I Know If I'm Having a Relapse?


Ask Your Friends

It is never really pleasant when somebody mentions that you seem "off" in some way. There are some people that bring it up out of genuine concern, while others seem to get a teeny bit of pleasure when they point out your trembling hands, word-finding difficulties or slow movements.

Whatever the intention or delivery, it is important to know what is going on with our symptoms. Because we may be so busy trying to carry on "business as usual" we may not realize that we have gotten worse in some way. Encourage those around you to be honest, even if it is not what you want to hear. It may be something as easily solved as moving inside to cooler temperatures or taking a nap.

Read the full article: Ask Your Friends




Acorda Therapeutics Presents Positive Data from Preclinical ...
MarketWatch - USA
Acorda's lead clinical product, Fampridine-SR, recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ...
See all stories on this topic


The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/question_buttonEN.gif” cannot be displayed, because it contains errors.

Treatment

Dr. Murray

Professor Emeritus of Medicine (Neurology)
View BIO


Q :
While I was trying to connect to the internet through the MSN site, there was a headline showing the top 10 most dangerous drugs in the states printed by the FDA. Interferon beta was #8 on that list. Is this really true?

A :
It would be surprising to see interferon beta on a list of dangerous drugs as it has been remarkably safe in the many years since its introduction to the therapy of MS, with hundreds of thousands of patients treated long term.
To those who made such a list I would immediately require an answer to the question, "What dangers, and what serious or fatal reactions have occurred?" There should be some documentation to such a statement, especially as it might cause some patients who would benefit from this very safe medication to avoid taking it when they would benefit in the short and long term for their disease. It wouldn't be a big concern if it was just an erroneous statement, which it is, but it has the potential to harm patients, so it is irresponsible.
In the reports on interferon beta, whether the carefully followed thousands of patients in clinical trials, or the hundreds of thousands of patients who have been on the drugs for years, there is only one that I know of that raised concerns for liver involvement and that was controversial as the patient was taking other drugs at the same time that were known to affect the liver. What other cases could they be referring to?
It would be interesting to know the website carrying this list as it deserves a response, in the interest of good patient care.
7/30/2008 8:56:42 AM
More answers from Dr. Jock Murray
More answers in the category: Treatment

http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2031

Biogen hopes to hit $4 billion revenue mark for 2008
Pharma Times (subscription) - London,UK
Biogen Idec has posted a strong set of financials for the second quarter which saw sales of the multiple sclerosis treatment Tysabri soar. ...
See all stories on this topic


Elan shares fall over Alzheimer's drug results
The Associated Press -
But the company said last week it is within a year of returning to profit thanks to the success of Tysabri, an MS drug developed in alliance with US ...
See all stories on this topic



Wheel to Walk group on quest to repair spinal cord injuries
Elliot Lake Standard - Elliot Lake,Ontario,Canada
Two researchers at McMaster University, doctors Michel Rathbone and Shucui Jiang head up the team. While some researchers in other countries were looking ...
See all stories on this topic



Researchers herald breakthrough data on Alzheimer's

By John Carroll

TauRx Therapeutics captured the center ring of attention at an international Alzheimer's meeting with new data for remberTM that demonstrates a dramatic ability to slow cognitive decline. Researchers say that remberTM slowed cognitive decline in 81 percent of the patients taking the drug, the first therapy to target the tau protein. And scientists at Aberdeen University in Scotland say that remberTM may well slow the brain's deterioration.

"This is an unprecedented result in the treatment of Alzheimer's disease," said Professor Claude Wischik. "We have demonstrated for the first time that it may be possible to arrest progression of the disease by targeting the tangles which are highly correlated with the disease."

Alzheimer's has proven to be one of the toughest diseases for developers to crack. On Monday Myriad Genetics announced that it would give up on Flurizan after it failed in a late-stage trial. Myriad spent $60 million on its effort to find a new therapy to treat Alzheimer's and will shell out an additional $8 million just shutting the program down. Flurizan was designed to reduce plaque, but patients in the trial did not demonstrate any improvement in cognition or daily activities when compared to a group taking a placebo.

- check out the release
- read the article from the Guardian
- for more on Myriad read this story from Forbes

ALSO: Elan and Wyeth, meanwhile, presented a full set of mid-stage data for their amyloid-clearing therapy bapineuzumab , saying that the data justified their decision to pursue advanced studies. But the Wall Street Journal says that experts may be underwhelmed by the data displayed at the International Conference on Alzheimer's Disease in Chicago. Shares of Elan slid on the news. Release | Report

Related Articles:
Alzheimer's vax eliminated plaque, not dementia
Big pharma sees big payback for Alzheimer's research
Genetic engineering ‘vacuums' Alzheimer plaque
Alzheimer's drug results boost Elan, Wyeth

Read more about: Alzheimer's, TauRx Therapeutics, RemberTM



Aging Hinders Memory Storage During Sleep Study in rats suggests brain needs 'experience replay' during slumber


HealthDay
By Robert Preidt
Tuesday, July 29, 2008

The image “http://www.healthday.com/Images/Editorial/Fac045ml.jpg” cannot be displayed, because it contains errors.TUESDAY, July 29 (HealthDay News) -- Aging hinders the consolidation of memories during sleep, a process that's crucial for the conversion of fresh memories into long-term ones, say University of Arizona researchers.

The researchers recorded activity in the hippocampus -- a brain region involved in learning and memory -- in 11 young and 11 old rats as they navigated mazes for food rewards. The rats' hippocampal activity was recorded again when they slept.

In the young rats, the sequence of neural activity recorded while they navigated the mazes was repeated while they slept. This was not the case in most of the older rats.

The researchers also found that among both young and old rats, those with the best sleep replay performed the best in their age groups on spatial memory tasks.

"This is the first study to suggest that an animal's ability to perform a spatial memory task may be related to the brain's ability to perform memory consolidation during sleep," study author Carol Barnes said in a Society for Neuroscience news release.

The study is in the July 30 issue of The Journal of Neuroscience.

"These findings suggest that some of the memory impairment experienced during aging could involve a reduction in the automatic process of experience replay," Michael Hasselmo, of Boston University, said in a Society for Neuroscience news release.

Identifying the specific memory deficit in the brains of older adults may be the first step to preventing age-related memory loss, he said.

"This study's findings could inspire the development and testing of pharmacological agents designed to enhance memory replay phenomena," Hasselmo said.

HealthDay
Copyright (c) 2008 ScoutNews, LLC. All rights reserved.
http://www.nlm.nih.gov/medlineplus/news/fullstory_67518.html

Yale Researchers Find New Trigger For Autoimmune Diseases

RPI-78M (Nutra Pharma / ReceptoPharm)

Nutra Pharma Announces Completion of Clinical Study in ...
Business Wire (press release) - San Francisco,CA,USA
“Completing this clinical trial is an important achievement for both Nutra Pharma and ReceptoPharm,” commented Paul Reid, CEO of ReceptoPharm. ...
See all stories on this topic

 

 

 

Yale Researchers Find New Trigger For Autoimmune Diseases
Yale University researchers have discovered a new way that autoimmune diseases like multiple sclerosis (MS) can be triggered, they reported Monday in the journal Proceedings of the National Academy of Sciences.


 

 

Smoking worsens the prognosis in multiple sclerosis

In this second paper on smoking and MS the authors found links with a worse clinical course.

authors: Sundström P, Nyström L.

source: Mult Scler. 2008 Jul 16. [Epub ahead of print]

read more

 

 

Smoking is a risk factor for early conversion to clinically definite multiple sclerosis

In this study the authors looked at people who had one attack suggestive of MS. They found that having a second attack was more common in people who smoked. The importance of the study is that smoking is a modifiable risk factor.

authors: Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly EJ, Munger KL, Deisenhammer F, Ascherio A, Berger T.

source: Mult Scler. 2008 Jul 16.

read more


 

Acorda Therapeutics to Host Conference Call to Report Second ...
Genetic Engineering News (press release) - New Rochelle,NY,USA
Acorda's lead clinical product, Fampridine-SR, recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ...
See all stories on this topic

 

 

Acorda Therapeutics to Host Conference Call to Report Second ...
Business Wire (press release) - San Francisco,CA,USA
Acorda’s lead clinical product, Fampridine-SR, recently completed a second Phase 3 clinical trial to evaluate its safety and efficacy in improving walking ...
See all stories on this topic

 

 

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

This paper found that loss of brain and cord tissue in people with secondary progressive MS is associated with a more severe clinical course. They suggested that MRI measures of atrophy may therefore be useful in future clinical trials.

authors: Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes RA, Smith KJ, Miller DH, Kapoor R.

source: Mult Scler. 2008 Jul 16.

read more


Regenerative medicine

 

Repair Stem Cell Institute Announces Top Global Stem Cell ...
Trading Markets (press release) - Los Angeles,CA,USA
One successful patient outcome is a professional golfer who had been diagnosed with multiple sclerosis. After receiving a repair stem cell treatment using ...
See all stories on this topic

 

 

Repair Stem Cell Institute Announces Top Global Stem Cell ...
istockAnalyst.com - Salem,OR,USA
One successful patient outcome is a professional golfer who had been diagnosed with multiple sclerosis. After receiving a repair stem cell treatment using ...
See all stories on this topic

 

 

ALS Therapy Development Institute and California Stem Cell, Inc ...
Earthtimes (press release) - London,UK
This effort is the latest in the two groups' on-going partnership to understand how stem cells, and their derivatives, may be used as part of a therapeutic ...
See all stories on this topic

 

 

New And Potentially Better Source Of Platelets For Transfusion
Clot-forming blood cells, or platelets, can drop to dangerously low levels in diseases such as anemia and in patients undergoing chemotherapy. To replace these critical cells, doctors filter platelets from donated blood, but this approach can increase the risk of transmitting blood infections and cause other side effects in patients who need frequent transfusions.


 

 

Statins Linked To Lower Dementia Risk
A US study that followed over 1,500 older Mexican Americans for 5 years found that statin users were about half as likely to develop dementia, or to have cognitive impairment without dementia, as those who did not use statins.

 

 

Alzheimer's Society Comment On Research Into Statins And Dementia
Statins are increasingly hitting the headlines as a potential cure for dementia. The jury is still out on how effective they are, but this study adds to growing evidence that they may have some benefits.

 

 

Drugs Commonly Used For Erectile Dysfunction Allowed More Chemotherapy To Reach Brain Tumors In Laboratory Animal Study
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.

 

 

Steep Rise In At Home Deaths As Patients Fail To Manage Their Medications
The sad loss of 28-year old movie actor Heath Ledger in January this year, who died from an accidental overdose of a prescription drug, brought to public attention the potential dangers of patients managing their own medications, which when combined with alcohol and street drugs, has resulted in a more than 3,000 per cent rise in home deaths due to medication errors, said US researchers in a new study.

Tuesday, July 29, 2008

Stem cell scientist predicts health revolution


Stem cell czar: UM researcher leads alternative effort

ftasker@MiamiHerald.com

Dr. Joshua Hare believes medicine is close to a goal long thought to be impossible: healing the human heart.

The way to get there? Stem cells.

''These could be as big as antibiotics were in the last century,'' says Hare, the researcher heading up the University of Miami's new Stem Cell Institute. ``Stem cells have the potential to have that kind of impact. Diseases like heart attacks, strokes, kidney failure, liver failure -- we will be able to transition them into things you live with.''

Hare spends his days peering through powerful microscopes, recruiting scientists from top universities and attending to patients betting on improving their conditions through his clinical trials.

Stem cells, only one-thousandth the size of a grain of sand, are the master cells of the body -- the source from which all other cells are created.

The most basic are embryonic stem cells, which are ''totipotent,'' meaning they can divide into any other type of cell -- heart tissue, brain tissue, kidney tissue -- all 220 cells that exist in the human body. They're controversial because when they are harvested, the embryo is destroyed, ending potential life.

But coming into view are new kinds of stem cells -- immature adult stem cells that can be extracted from bone marrow, from organs such as the heart or kidney or even from the skin. These can be taken without destroying embryos.

While researchers until recently believed adult stem cells were limited because they could develop only into cells similar to them -- bone marrow cells only into blood cells, for example -- evidence is growing that they, too, may become the tissue for hearts, brains, kidneys and other organs.

Here are the three sources of adult stem cells and their varying potentials:

Bone marrow stem cells: These are considered ''multipotent.'' Most researchers believe they can become heart tissue. Some feel they also can change themselves into kidney, brain or other organ cells -- although perhaps not all organs.

Organ stem cells: These cells are taken from tissue in hearts, kidneys and other organs. Some researchers believe they are also ''multipotent,'' meaning that a heart stem cell can turn into a brain or kidney or other cell, although not all 220 of the body's cells.

Skin cells: Stem cells taken from the skin, with genetic modification, may also be ''totipotent'' -- just as able as embryonic stem cells to turn into all 220 types of cells in the human body, new research indicates.


Dr. Hare expounds on these developments:

Q. You've said that the basic idea behind your stem cell work is that a healthy human body is creating stem cells all the time to keep its organs healthy, and you're trying to tap into this ability to expand its powers?

A: That's the theory. It does sound fantastic. Actually, it happens in the body all the time, in tiny amounts. In our blood, to survive, we have red blood cells that carry oxygen, white cells that regulate the immune system and platelets, which are tiny cells that seal off cuts. They come from stem cells in the bone marrow. [The marrow is the source for all red blood cells, platelets and some white blood cells.]

The cells circulate in the blood all the time. Unless there's a signal that says, 'Come here and do this,' they will just keep circulating. If you get a cut, the cells will be recruited to that area to do what they do.

Q:Could such cells heal a heart attack all by themselves?

A: Experts believe the ability of the body to heal itself without help is limited. The system can slowly replace missing cells here and there, over a lifetime. But it's not designed to repair a massive injury like a heart attack. That's where we as doctors can intervene.

Q: In fact, you are intervening. You've led two studies at Johns Hopkins University and University of Miami in which you have harvested immature, or ''mesenchymal'' adult stem cells from the bone marrow, multiplied them many times in the lab, then injected them into the damaged heart. Is the idea that the bone marrow stem cells become heart cells?

A: This is where the biology gets somewhat murky. We don't understand all the elements. We do have evidence that the cells differentiate [develop] into healthy heart tissue.

Q:And this could be true with a damaged liver, kidney or brain?

A: In theory.

Q: And, while so far you've had to inject the bone marrow stem cells directly into the heart duringsurgery, you now have FDA approval for using a catheter to inject the stem cells via the groin?

A: That's right.

Q:You've said other kinds of adult stem cells are at work too?

Hare: Many cells are involved in the body's attempts to heal itself. Some are from blood cells from bone marrow. But also, within the organs themselves, there are resident precursor cells that are stem cells. They're sitting there like front-line soldiers in an injury. We think those cells form collections that talk to each other and can go out and do healing. So we are engaging in a new study that will look at cardiac stem cells.

We can take pieces [of heart tissue] during surgery, multiply the stem cells in the lab and have a large amount we can give back to the patient.

Q: Could an organ stem cell from, say, heart tissue, become a stem cell in the brain or kidney?

A: It's possible, but not certain. We're interested in studying how many degrees of freedom these cells have.

Q: And now researchers are getting stem cells even from the skin?

A: We're starting to look at that. We know that stem cells in the skin replenish every 120 days. Researchers a year ago took regular stem cells from the skin and genetically reprogrammed them by introducing four genes. They were able to turn them into stem cells with a nearly unlimited capacity.

Q:If this works, won't it do away with the need for embryonic stem cells?

A: There are lots of problems with it. It's a genetic modification. Whenever you do that, it introduces a whole new area of concern. Recent reports say animals treated with these cells have a very high risk of cancer.

Q: If embryonic stem cells do turn out to be best, will it be because they are the best at differentiating -- that is, turning into other kinds of cells?

A: Exactly right. That's the theoretical reason they should be best, and there are stats that back that up. An embryonic stem cell is at a state that it can make a whole organism. You can make a whole mouse out of an embryonic stem cell. There are 220 cells in the human body, and embryonic stem cells can make each and every one of them.

The issue I've always worried about is do you want to make every cell in the body. That could increase the risk of cancer. What I like about our approach is that it is targeted. We're trying to heal the heart.

Join the discussion

The Miami Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from personal comments and remarks that are off point. In order to post comments, you must be a registered user of MiamiHerald.com. Your username will show along with the comments you post. Not a registered user? It's Free! Register here. Thank you for taking the time to offer your thoughts.

Recent Comments

Be the first to post a comment using the form below

Post Your Comment

Teva earnings driven once again by strong Copaxone sales

Teva earnings driven once again by strong Copaxone sales

Israel's Teva Pharmaceutical Industries has posted another strong set of financials for the second quarter, with net income rising 5% to $539 million, or $0.65 per share (+3%)
read more
http://www.pharmatimes.com/WorldNews/article.aspx?id=14021&src=EWorldNews

 



Atlantic man brings Lincoln to life
Daily Nonpareil - Council Bluffs,IA,USA
Williams and his wife, Jeanie, also cope with her multiple sclerosis. She is a registered nurse, and together the couple formed another part-time business ...
See all stories on this topic

 

"Debemos ser cautos con las células madre"
Gaceta Médica - Madrid,Spain
Tenemos algunos realmente novedosos, y posiblemente más efectivos que el interferón beta, como los nuevos antimicóticos, o el fingolimod, ...
See all stories on this topic
Montreal08 coming soon!

Montréal08 – Living with MS: Global Perspectives on Current Issues, Tuesday 16 September 2008.

read more

 

Successful ICF Core Sets for MS conference in Switzerland

The International Classification of Functioning, Disability and Health (ICF) Core Sets for MS Consensus Conference took place from 2-4 May, 2008 at the Valens Rehabilitation Centre.

read more

 



Research News
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

In this multicentre randomised controlled trial the authors studied the effect of intravenous immunoglobulin in people with relapsing remitting MS. Unfortunately it was not of benefit.

authors: Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group.

source: Neurology. 2008 Jul 22;71(4):265-71.

read more

 

 

A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele

The pathology of MS is complex and genes play a role. The authors have developed a new technique to identify those genes that might contribute to risk.

authors: Goris A, Walton A, Ban M, Dubois B, Compston A, Sawcer S.

source: Tissue Antigens. 2008 Jul 15.

read more

 

 

Natural history of multiple sclerosis in a population-based cohort

This study looked to see which factors were important in predicting outcome in MS. They found that having the relapsing remitting form, complete recovery from the first relapse, and younger age of onset predicted better clinical outcome.

authors: Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F; for the LORSEP Group.

source: Eur J Neurol. 2008 Jul 15.

read more

 

 

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

This study compared the differences in exposure to different viruses in people with MS and a related but more severe condition called neuromyelitis optica. They found different antibody responses and concluded that this offered further evidence that the conditions are distinct.

authors: Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger K, Petereit H, Maurer M, Tumani H, Vincent A, Eichhorn P, Brigitte W, Wick M, Voltz R.

source: J Neurol Neurosurg Psychiatry. 2008 Jul 17.

read more


 

Smoking is a risk factor for early conversion to clinically definite multiple sclerosis

In this study the authors looked at people who had one attack suggestive of MS. They found that having a second attack was more common in people who smoked. The importance of the study is that smoking is a modifiable risk factor.

authors: Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, O'Reilly EJ, Munger KL, Deisenhammer F, Ascherio A, Berger T.

source: Mult Scler. 2008 Jul 16.

read more



 

 

Prevalence of sleep problems in individuals with multiple sclerosis

In this study the authors investigated the presence of sleep disorders among people with MS, finding them to be more frequent than in the general population.

authors: Bamer AM, Johnson KL, Amtmann D, Kraft GH

source: Mult Scler. 2008 Jul 16.

read more


 

 

Smoking worsens the prognosis in multiple sclerosis

In this second paper on smoking and MS the authors found links with a worse clinical course.

authors: Sundström P, Nyström L.

source: Mult Scler. 2008 Jul 16. [Epub ahead of print]

read more

 

 

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

This paper found that loss of brain and cord tissue in people with secondary progressive MS is associated with a more severe clinical course. They suggested that MRI measures of atrophy may therefore be useful in future clinical trials.

authors: Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes RA, Smith KJ, Miller DH, Kapoor R.

source: Mult Scler. 2008 Jul 16.

read more

 

 

MS News

Summaries of MS news from websites around the world.

New EU air travel regulations for people with disabilities

source: European Platform of MS

The European Disability Forum (EDF) has successfully campaigned to improve the rights of air passengers with disabilities.

read more

Statins could cut the risk of developing dementia – study
People at high risk for dementia who took cholesterol-lowering statins are half as likely to develop dementia, according to a new study

 

 


 

 


The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/en_logoEN.gif” cannot be displayed, because it contains errors. The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/fr_logoEN.gif” cannot be displayed, because it contains errors. The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/headerEN.gif” cannot be displayed, because it contains errors.

Diagnosis and Types of MS
The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/question_buttonEN.gif” cannot be displayed, because it contains errors.

Dr. Freedman

Professor of medicine in the field of neurology at the University of Ottawa, ON
View BIO


 

Q :
Since it is not always easy to diagnose MS, how are people recruited for studies that are looking at treatment of Clinically Isolated Syndrome?

A :
Clinically isolated syndrome refers to one of the classical presentations of the “first attack” of MS. By definition, one needs to have events that involve different parts of the central nervous system involved at different times to meet the criteria for diagnosis. Patients who are having their first attack would not meet this definition. Many such patients though will have MRI studies that strongly point to MS as a possibility and such patients will most likely go on to have other attacks within a few years. The only way these patients are recruited to studies is that they have had all other causes for their neurological symptoms and signs ruled out. If their brain MRIs then show MS-type lesions they would be recruited to the studies.
7/29/2008 8:44:09 AM
More answers from Dr. Mark Freedman
More answers in the category: Diagnosis and Types of MS

DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca


http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2030

 


 
Patient groups play lead role in research programs
By John Carroll

Jay Tenenbaum wanted to do much more than help raise money for cancer research after his diagnosis for melanoma. He believes groups of patients like himself can advance new therapeutics that can save their lives. The multimillionaire created CollabRx with $2 million of his own money and is raising $3 million more. And Tenenbaum is hoping to create a group of "virtual" biotechs that can advance new research into life-saving therapies.

Patient-supported research efforts like his are having a real impact on the drug discovery arena, the Wall Street Journal reports. The Myelin Repair Foundation has provided $13 million to fund a team of researchers who will unveil their top two prospects to drug developers later this year. And the Cystic Fibrosis Foundation has supplied $75 million to advance a drug that has shown promise in clinical trials.

- read the article from the Wall Street Journal

Related Article:
PTC gets $25M drug development award
Foundation invests millions to find MS drug leads

Read more about: patient groups, Jay Tenenbaum

http://lists.fiercemarkets.com/c.html?rtr=on&s=69l,113uq,1m5f,e56k,d3q3,3lig,k6n4

 


 
 
CROs play growing role in early-stage research
By John Carroll

Contract research organizations are playing a growing role helping small biotech companies develop early-stage therapeutics, according to a new report from Turner Investment Partners. Over the past five years the global CRO industry has seen its revenue share from biotech companies grow from 21 percent to 30 percent. And regulators have shown a preference for the broad patient groups that international CROs can offer.

On a darker note, the TIP report also underscores that a falling rate of new drug approvals at a time of soaring costs is causing pharma companies to lose interest in their R&D operations. And that, they say, is a disaster in the making.

"Pharma companies must innovate to survive" says the report, "which means that while they are striving to control costs, they also need to keep spending on research and development to create profitable, proprietary new drugs and replenish the pipeline."

- read the report from In-PharmaTechnologist

Related Articles:
CRO worries grow as research business booms
CRO market hits $14B
New companies flooding CMO market

Read more about: R&D spending, early-stage research, CRO

http://lists.fiercemarkets.com/c.html?rtr=on&s=69l,113uq,1m5f,gatr,3z7g,3lig,k6n4

 



 

Stem cell scientist predicts health revolution

By John Carroll

Dr. Joshua Hare, who heads the new stem cell institute at the University of Miami, says that stem cells could have as big an impact on human health as antibiotics had in the 20th century. "Diseases like heart attacks, strokes, kidney failure, liver failure--we will be able to transition them into things you live with," says the researcher.

One of Hare's projects involved harvesting adult stem, multiplying them and then injecting them into a damaged heart, working on the theory that they would develop into new heart tissue that could heal the damage. And he now has the FDA's OK to experiment with new ways to introduce stem cells.

- read the story from the Miami Herald

ALSO: A group of scientists in Australia are studying ways to use stem cells to treat chronic angina in patients who have failed other remedies. Report

Related Articles:
In breakthrough, scientists reprogram skin cells into ESCs
Stem cell revolutionaries take on big challenges
More jaw-dropping scientific advances lay ahead
In research, stem cells make another breakthrough

Read more about: Stem Cells, Dr. Joshua Hare


http://www.fiercebioresearcher.com/story/stem-cell-scientist-predicts-revolution-human-health/2008-07-29?utm_medium=nl&utm_source=internal&cmp-id=EMC-NL-FBR&dest=FBR


 




 

Fish-Heavy Diet May Slow Hardening of Arteries 
PITTSBURGH -- A diet loaded with omega-3 fatty acids from fish may prevent atherosclerosis over a lifetime, researchers found. full story

http://www.medpagetoday.com/PrimaryCare/DietNutrition/tb/10300



 

FDA Warns of Toxic Tomalley in Maine Lobsters 
ROCKVILLE, Md. -- The FDA warned today against eating the soft, green substance found in the body cavity of Maine lobsters, called tomalley, which is considered a delicacy by some. But the meat of the claw and tail were not part of the caution. full story

http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/tb/10306

 

 

Alzheimer’s Linked to Thyroid-Related Hormone 
BOSTON -- Abnormal levels of the hormone thyrotropin, which controls thyroid function, may be associated with an increased risk of Alzheimer’s disease in women, researchers found. full story

http://www.medpagetoday.com/Endocrinology/Thyroid/tb/10293

Monday, July 28, 2008

MBP8298


New drug offers hope for severe MS sufferers
Chicago Daily Herald - Chicago,IL,USA
The drug being studied in the clinical trial is known as MBP8298. In earlier trials in Canada and Europe, it has shown promise as a treatment for ...
See all stories on this topic

Daily Herald | New drug offers hope for severe MS sufferers

By Matt Arado | Daily Herald Staff

Every day, Bloomingdale resident Erin Zwirlein grabs a cane and goes for a one-mile walk.

Erin Zwirlein of Bloomingdale has MS and is taking an experimental drug for treatment. Here, she gets a hug from her daughter Morgan, 9.
Bev Horne | Staff Photographer
previous image
previous image
next image
next image


Erin Zwirlein of Bloomingdale has MS and is taking an experimental drug for treatment. Here, she gets a hug from her daughter Morgan, 9.

Bev Horne | Staff Photographer

She returns to her townhouse tired, a bit unsteady, but happier than she ever thought possible.

Zwirlein, 36, has the worst kind of multiple sclerosis: the "secondary-progressive" type, defined by a steady and relentless worsening of the disease without any periods of improvement.

As recently as last year, the disease wouldn't let her complete a one-mile walk. Even a shorter one could leave her too tired to stand up.

The difference between then and now is that today, Zwirlein is a participant in a clinical trial of a new drug that doctors hope will be the first to offer viable relief to people with her type of MS.

"I feel so good," she said. "It's like I'm getting my life back."

Zwirlein doesn't know for sure that she's actually getting the drug; half of the 510 patients in the trial get the drug and the other half, a placebo. But she feels good about her chances.

"I'm a positive person," she said. "But I don't think my brain could make these improvements happen on its own."

Dr. Daniel Wynn, the Northbrook physician who invited Zwirlein to participate in the trial, said the drug is one of the most exciting developments he's seen in his 30 years of involvement with MS research.

Up to now, the only existing treatment for secondary-progressive MS is a chemotherapy agent that has limited use because of its toxic effects on the heart. In earlier trials, the only side effect that the new drug has caused is a harmless and temporary flushing of the skin, he said.

"This could be a gigantic advance," Wynn said. "To have something that will help those with the worst form of a terrible disease is a very big deal."

First symptoms

MS remains a mysterious disease, even though roughly 200 people are diagnosed with it each week. Medical experts believe that in MS patients, the body's immune system inappropriately attacks the healthy tissue that coats nerves in the brain and spinal column. The result is an unpredictable, wide-ranging array of symptoms that includes abnormal fatigue, tremors, vision problems and muscle failure. There still is no cure for the disease.

Zwirlein's symptoms first appeared in 1999, when she lived in Wisconsin with her husband and infant daughter.

She experienced bouts of disorienting vertigo. She had trouble keeping her balance. And in a particularly frightening instance, she dropped her baby.

"My arms just gave out," she said. "It was like I didn't have any control. I knew that wasn't normal."

When the diagnosis came, it hit Zwirlein hard. She fell into a near-depression, wondering if her life was coming to an end.

"I went through a period where I'd just start bawling," she said. "It was very bad."

Soon, though, Zwirlein realized she had a choice: Let the disease take over her life, or fight. She decided to fight.

"I'm not the type to just do nothing," Zwirlein said.

So she worked with her doctors on a drug treatment plan. Like most people with MS, Zwirlein was initially diagnosed with the "relapse-remitting" form, in which MS "flare-ups" alternate with periods of recovery. The FDA has approved a number of drugs that can slow the frequency and intensity of attacks in people with this type of the disease.

While undergoing treatment, Zwirlein stayed active. She went back to work, taking a job as a welder in a factory. And she wouldn't let anyone feel sorry for her.

"It might have been a pride thing, but I didn't want anyone to treat me special," she said. "We had a scooter in our garage, but I refused to use it. During a trip to Ireland, I refused to get in a wheelchair, no matter how tired I got. I wanted to show everyone that I was still alive, even though I had this disease."

Zwirlein's fight hit a roadblock when her marriage began to crumble. In 2004, she left her husband and brought her daughter, Morgan, with her to Bloomingdale. The move put her six hours away from her doctors, left her without a job and sparked a stressful custody battle with her husband.

At the same time, Zwirlein's symptoms worsened. The leg brace she'd been wearing for support was no longer enough; she often had to use a cane when she walked. Occasionally, Zwirlein became so weak that she could move only by crawling on the floor.

Searching for a doctor close to home, Zwirlein discovered Wynn's medical office, Consultants in Neurology. She underwent a screening, which revealed some bad news: The disease had advanced to the secondary-progressive stage.

Still, Zwirlein didn't give up hope. She wasn't about to let the disease ruin the new life she was trying to create for herself and Morgan. When Wynn told her about the clinical trial, she jumped at the chance.

"I told Dr. Wynn that the one thing I wanted was to run again with my daughter," Zwirlein said. "I would do anything to make that happen. I know that the trial is a roll of the dice, but Morgan's suffered enough through all this. She's probably suffered most of all."

'You can't give up'

The drug being studied in the clinical trial is known as MBP8298. In earlier trials in Canada and Europe, it has shown promise as a treatment for secondary-progressive MS.

"It appears to slow the progression by five years or more," Wynn said. "That would have a huge impact on people with this form of MS. It could mean the difference between using a cane and using a walker. Or using a walker and using a wheelchair."

Wynn said that the drug seems to defuse the immune system's impulse to attack healthy tissue, similar to how allergy medications stop the body from reacting to pollen or ragweed.

It takes just a few minutes to administer the drug via an IV, and it has not produced any serious side effects so far, Wynn said.

The trial is scheduled to last two years, but Wynn hopes the FDA will approve the drug early once results from the Canada and Europe trials are finalized.

Zwirlein reports that since starting the trial in January, she feels stronger and walks better. She still wears a brace, but she sometimes can complete a one-mile walk without the help of a cane.

"I can't quite run with Morgan yet," she said with a laugh. "But I'm getting there."

Zwirlein hopes that her battle with the disease will inspire other MS patients to keep up the fight, even when things look grim. Toward that end, she's written an article for a medical magazine that takes a humorous look at her experiences.

"You can't give up. You have to keep up the drive to make yourself better," she said. "I sometimes feel like God gave this disease to me because other people just couldn't handle it."

Zwirlein misses working, and getting a job remains at the top of her priority list for the future. She knows it will be tough, especially because of persistent misconceptions about her disease.

"It's funny - people think that your brain doesn't work anymore, that you can't do anything, that you won't strive for anything," she said. "I hope I can show people how wrong that is."

http://www.dailyherald.com/story/?id=223439&src=120



Tysabri

Elan reports 31800 Tysabri patients
Irish Times - Dublin,Ireland
Biotech company Elan, Ireland's biggest drugmaker, said 31800 patients were using its multiplesclerosis treatment Tysabri at the end of June. ...
See all stories on this topic

\Elan revenues boosted by Tysabri sales
Ireland Digital - UK
Elan Corp, the Irish drugmaker, said its first quarter financial results were boosted by sales of the MS drug Tysabri. The drug achieved market sales of ...
See all stories on this topic


The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/en_logoEN.gif” cannot be displayed, because it contains errors. The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/fr_logoEN.gif” cannot be displayed, because it contains errors.

The image “http://www.msanswers.ca/App_Themes/AskTheExpert_English/Images/question_buttonEN.gif” cannot be displayed, because it contains errors. Daily Living with MS

Ms. Chadha

Director of Litigation, ARCH Disability Law Centre
View BIO

Q :
A friend of ours in the UK has asked if we can help provide information to a friend of hers who would dearly love to move permanently to Canada. The potential candidate is fully employed as a web designer. However, she has MS.
Given the considerations for medical review that applicants for Permanent Residency must undergo, is MS an absolute ground for refusal of application (perhaps from the ' undue burden to Canadian health services' provision?)

A :
I am unable to definitely state whether a person with MS would be denied permanent residency status in Canada.
Most persons who are applying to immigrate to Canada must undergo a medical examination. Under section 38(1)(c) of the Immigration and Refugee Protection Act (IRPA), an applicant’s medical condition would be tested against three health grounds for inadmissibility:
danger to public health,
danger to public safety, and
excessive demand on health or social services.

If the person with a disability is being sponsored to come to Canada and is the spouse or dependent child of the sponsor, the test of “excessive demand on health or social services” may not be applied in that person’s application.
While each applicant is to be assessed on an individual basis and the unique circumstances and medical history of the individual’s condition are to be considered, the estimated cost arising from the individual’s condition is evaluated against a pre-determined figure that the government has established. This figure is determined by the government’s evaluation of the per capita costs of health care for the applicant’s age and gender applied over a certain time period.

I am aware of one Canadian Federal Court case that was determined under a former immigration statute wherein an applicant was denied permanent residence in Canada due to MS because of the costs associated with on-going monitoring of MS and the medicine that is used in the treatment of MS. This Federal Court judgment was not appealed.

In a subsequent Supreme Court of Canda Case decision, the Supreme Court held that non-medical factors such as the availability, scarcity or cost of publicly funded services along with the willingness and ability of an applicant or his or her family to pay for the cost of private support should be taken into consideration when determining if someone is medically inadmissible. The applicant in this case was a dependent child with a developmental disability. In this case, the Supreme Court noted that since the applicant had a developmental disability, he would be accessing Canadian social services rather than health care. In addition, the primary applicant (the child’s father) was a business applicant so the family’s financial status was a significant factor in the application process. The Supreme Court sent this family’s application back to Canada Immigration for reconsideration and the application has not yet been finally determined.

Unfortunately, a long line of Canadian caselaw reveals that applicants with disabilities are often denied admission to Canada because of the costs associated with medical and rehabilitative care and disability aids and equipment. Serious health conditions requiring on-going care, treatment or hospitalization are likely to be considered inadmissible because the costs of care, treatment and hospitalization would likely be much greater than the per capita costs of that the applicant’s age or gender to the Canadian health-care system.

There is a lot of information about applying for permanent residency available on Citizenship and Immigration Canada’s website which your friend may wish
to read at: http://www.cic.gc.ca.
7/29/2008 1:11:14 AM
More answers from Ms. Ena Chadha
More answers in the category: Daily Living with MS

http://www.msanswers.ca/QuestionView.aspx?L=2&QID=647


Multiple Sclerosis

Biovail's Melnyk Drops Board Challenge and Will Start New Firm
Bloomberg - USA
Biovail will cut costs and focus on drugs for central nervous system disorders, including multiple sclerosis. Melnyk wanted to pursue hard-to-formulate ...
See all stories on this topic

MS Rollerblade race expected to top $8000
Thunder Bay's Source - Thunder Bay,Ontario,Canada
The event was expected to raise about $8000 for Multiple Sclerosis sufferers in this area and organizers Laura Zaina and Hal Lightwood said they had hoped ...
See all stories on this topic

Brunswick police will Pedal to the Point
The Plain Dealer - cleveland.com - Cleveland,OH,USA
Seven city police officers who call themselves "The Choir Boys" will be pedaling 75 miles in August to raise money for the National Multiple Sclerosis ...
See all stories on this topic

Hope for MS sufferers as city scientist nears breakthrough
Scotsman - United Kingdom
By GARETH ROSE AN Edinburgh scientist is nearing a breakthrough that will revolutionise the treatment of Multiple Sclerosis and change the lives of ...
See all stories on this topic


Locals take part in MS bike tour
Windsor Star - Ontario, Canada
The Grand Bend to London ride is The Multiple Sclerosis Society's largest fundraiser in Southwestern Ontario. Last year, it raised over $860000.
See all stories on this topic

Giving Something Each Day May Keep the Doctor Away
PR Web (press release) - Ferndale,WA,USA
Woman with Multiple Sclerosis sends healing message and starts a worldwide giving movement with 29-Day Giving Challenge. Givers commit to the Challenge and ...
See all stories on this topic



Hope for MS sufferers as city scientist nears breakthrough
Scotsman - United Kingdom
By GARETH ROSE AN Edinburgh scientist is nearing a breakthrough that will revolutionise the treatment of Multiple Sclerosis and change the lives of ...
See all stories on this topic

Unproven stem cell therapy has its devotees
Toronto Star - Ontario, Canada
After doctors at home and elsewhere in Canada were unable to help her, attributing her increasing pain and muscle loss to multiple sclerosis, MacVicar began ...
See all stories on this topic

Hope for MS sufferers as city scientist nears breakthrough

Published Date: 28 July 2008

By GARETH ROSE

AN Edinburgh scientist is nearing a breakthrough that will revolutionise the treatment of Multiple Sclerosis and change the lives of generations of future sufferers.

Edinburgh University's Professor Charles ffrench-Constant, whose work has largely been funded with £2 million from the author JK Rowling, below, is working on a way of using stem cells to halt the deterioration of sufferers.
He is carrying out tes

ts on mice and rats to try to find a way of using the cells to repair damage to the brain.
Combined with the earliest possible detection of MS in patients, Prof ffrench-Constant's work offers the best hope of eradicating its devastating effect on patients.

He recently appeared in a documentary made by journalist and MS sufferer Elizabeth Quigley, who sees his tests as a possible "cure", although sadly for future generations rather than herself.

Prof ffrench-Constant, head of the Edinburgh University Centre for Translational Research, is reluctant to talk so boldly, but is confident that progress can be made in combating the disease which affects about 10,000 Scots.
He said: "We need to identify targets – molecules that contribute to the repair process in the brain. We have identified one interesting new candidate and are progressing with that, as well as trying to identify others.


"Once we have a positive target we have to see if it is present in patients with MS, we can't assume that just because it's worked on rats and mice.
"The MS Society has a brain bank with lots of tissues from people who have died from MS. If it is present we would run tests to see whether manipulating the target would have the result we hope. Then we would have the long, complicated process of developing the drug."

This means a treatment being available to patients in the UK is likely to be ten or 15 years away, although, for many people living with a history of MS in their family that will be a comforting thought.
Where MS comes from and what triggers it remains a mystery, but it is believed to be at least partly hereditary.

It is sometimes known as the "Scottish disease" as this country has the highest concentration in the world. It can also be found abroad in areas which have a large Scottish community.

Countries with a similar latitude to Scotland also have high rates of MS, suggesting that temperature or sunlight could be a factor, and childhood illnesses are also common among sufferers who develop MS in later life.
About 85,000 people in the UK suffer from MS, the result of damage to myelin, which blocks signals from the brain, prohibiting things like movement and speech.
A drug that could undo that damage remains the stuff of science fiction, but Prof ffrench-Constant believes something that could stop further degeneration is within reach.

This combined with early detection to ensure sufferers are treated when their health is still relatively good, could seriously limit the effect MS will have on future generations.
Ms Rowling, whose mother died in 1990 from respiratory problems linked to MS, has said:
"It would mean everything to me if I thought that as a result even one person did not have to go through what my mother did."
Mark Hazelwood, director of MS Society Scotland, said: "The MS Society Scotland was delighted to be able to provide £2 million funding to help establish this important and groundbreaking centre in Edinburgh."

The full article contains 585 words and appears in Edinburgh Evening News newspaper.

Page 1 of 1

  • Last Updated: 28 July 2008 10:55 AM
  • Source: Edinburgh Evening News
  • Location: Edinburgh

http://news.scotsman.com/health/Hope-for-MS-sufferers-as.4330432.jp

Instant Expert: The Human Brain

The Human Brain

Instant Expert: The Human Brain

  • 11:58 04 September 2006
  • NewScientist.com news service
  • Helen Philips

http://www.newscientist.com/channel/being-human/brain/dn9969


The Human Brain - With one hundred billion nerve cells, the complexity is mind-boggling. Learn more in our cutting edge special report.

The brain is the most complex organ in the human body. It produces our every thought, action, memory, feeling and experience of the world. This jelly-like mass of tissue, weighing in at around 1.4 kilograms, contains a staggering one hundred billion nerve cells, or neurons.

The complexity of the connectivity between these cells is mind-boggling. Each neuron can make contact with thousands or even tens of thousands of others, via tiny structures called synapses. Our brains form a million new connections for every second of our lives. The pattern and strength of the connections is constantly changing and no two brains are alike.

It is in these changing connections that memories are stored, habits learned and personalities shaped, by reinforcing certain patterns of brain activity, and losing others.

Grey matter

While people often speak of their "grey matter", the brain also contains white matter. The grey matter is the cell bodies of the neurons, while the white matter is the branching network of thread-like tendrils - called dendrites and axons - that spread out from the cell bodies to connect to other neurons.

But the brain also has another, even more numerous type of cell, called glial cells. These outnumber neurons ten times over. Once thought to be support cells, they are now known to amplify neural signals and to be as important as neurons in mental calculations. There are many different types of neuron, only one of which is unique to humans and the other great apes, the so called spindle cells.

Brain structure is shaped partly by genes, but largely by experience. Only relatively recently it was discovered that new brain cells are being bornneurogenesis. The brain has bursts of growth and throughout our lives - a process called then periods of consolidation, when excess connections are pruned. The most notable bursts are in the first two or three years of life, during puberty, and also a final burst in young adulthood.

How a brain ages also depends on genes and lifestyle too. Exercising the brain and giving it the right diet can be just as important as it is for the rest of the body.

Chemical messengers

The neurons in our brains communicate in a variety of ways. Signals pass between them by the release and capture of neurotransmitter and neuromodulator chemicals, such as glutamate, dopamine, acetylcholine, noradrenalin, serotonin and endorphins.

Some neurochemicals work in the synapse, passing specific messages from release sites to collection sites, called receptors. Others also spread their influence more widely, like a radio signal, making whole brain regions more or less sensitive.

These neurochemicals are so important that deficiencies in them are linked to certain diseases. For example, a loss of dopamine in the basal ganglia, which control movements, leads to Parkinson’s disease. It can also increase susceptibility to addiction because it mediates our sensations of reward and pleasure.

Similarly, a deficiency in serotonin, used by regions involved in emotion, can be linked to depression or mood disorders, and the loss of acetylcholine in the cerebral cortex is characteristic of Alzheimer’s disease.

Brain scanning

Within individual neurons, signals are formed by electrochemical pulses. Collectively, this electrical activity can be detected outside the scalp by an electroencephalogram (EEG).

These signals have wave-like patterns, which scientists classify from alpha (common while we are relaxing or sleeping), through to gamma (active thought). When this activity goes awry, it is called a seizure. Some researchers think that synchronising the activity in different brain regions is important in perception.

Other ways of imaging brain activity are indirect. Functional magnetic resonance imaging (fMRI) or positron emission tomography (PET) monitor blood flow. MRI scans, computed tomography (CT) scans and diffusion tensor images (DTI) use the magnetic signatures of different tissues, X-ray absorption, or the movement of water molecules in those tissues, to image the brain.

These scanning techniques have revealed which parts of the brain are associated with which functions. Examples include activity related to sensations, movement, libido, choices, regrets, motivations and even racism. However, some experts argue that we put too much trust in these results and that they raise privacy issues.

Before scanning techniques were common, researchers relied on patients with brain damage caused by strokes, head injuries or illnesses, to determine which brain areas are required for certain functions. This approach exposed the regions connected to emotions, dreams, memory, language and perception and to even more enigmatic events, such as religious or "paranormal" experiences.

One famous example was the case of Phineas Gage, a 19th century railroad worker who lost part of the front of his brain when a 1-metre-long iron pole was blasted through his head during an explosion. He recovered physically, but was left with permanent changes to his personality, showing for the first time that specific brain regions are linked to different processes.

Structure in mind

The most obvious anatomical feature of our brains is the undulating surfac of the cerebrum - the deep clefts are known as sulci and its folds are gyri. The cerebrum is the largest part of our brain and is largely made up of the two cerebral hemispheres. It is the most evolutionarily recent brain structure, dealing with more complex cognitive brain activities.

It is often said that the right hemisphere is more creative and emotional and the left deals with logic, but the reality is more complex. Nonetheless, the sides do have some specialisations, with the left dealing with speech and language, the right with spatial and body awareness.

See our Interactive Graphic for more on brain structure

Further anatomical divisions of the cerebral hemispheres are the occipital lobe at the back, devoted to vision, and the parietal lobe above that, dealing with movement, position, orientation and calculation.

Behind the ears and temples lie the temporal lobes, dealing with sound and speech comprehension and some aspects of memory. And to the fore are the frontal and prefrontal lobes, often considered the most highly developed and most "human" of regions, dealing with the most complex thought, decision making, planning, conceptualising, attention control and working memory. They also deal with complex social emotions such as regret, morality and empathy.

Another way to classify the regions is as sensory cortex and motor cortex, controlling incoming information, and outgoing behaviour respectively.

Below the cerebral hemispheres, but still referred to as part of the forebrain, is the cingulate cortex, which deals with directing behaviour and pain. And beneath this lies the corpus callosum, which connects the two sides of the brain. Other important areas of the forebrain are the basal ganglia, responsible for movement, motivation and reward.

Urges and appetites

Beneath the forebrain lie more primitive brain regions. The limbic system, common to all mammals, deals with urges and appetites. Emotions are most closely linked with structures called the amygdala, caudate nucleus and putamen. Also in the limbic brain are the hippocampus - vital for forming new memories; the thalamus - a kind of sensory relay station; and the hypothalamus, which regulates bodily functions via hormone release from the pituitary gland.

The back of the brain has a highly convoluted and folded swelling called the cerebellum, which stores patterns of movement, habits and repeated tasks - things we can do without thinking about them.

The most primitive parts, the midbrain and brain stem, control the bodily functions we have no conscious control of, such as breathing, heart rate, blood pressure, sleep patterns, and so on. They also control signals that pass between the brain and the rest of the body, through the spinal cord.

Though we have discovered an enormous amount about the brain, huge and crucial mysteries remain. One of the most important is how does the brain produces our conscious experiences?

The vast majority of the brain’s activity is subconscious. But our conscious thoughts, sensations and perceptions - what define us as humans - cannot yet be explained in terms of brain activity.

http://www.newscientist.com/channel/being-human/brain/dn9969




Perspectives in Central Nervous System Malignancies

These 4 podcasts provide additional insights into the PCNSM4: Perspectives in Central Nervous System Malignancies conference, which discussed trends and treatment strategies associated with the management of CNS malignancies.
Source: Johns Hopkins Advanced Studies in Medicine (JHASiM) [more]
http://broadcaster.medpagetoday.com/t?r=2&c=1926&l=15&ctl=CE03:961584531C0AE5127C71226B5A752E52

Depression News The Health Benefits Of Daughters-In-Law On Chinese Elders
In a new twist on the Confucian ideal of filial piety, a study finds that the assistance of daughters-in-law - but not their own children - helps mitigate depression among older people in China.
Anxiety / Stress News
Reducing Stress Can Bolster Immune System In HIV-Positive Adults, Others
CD4+ T lymphocytes, or simply CD4 T cells, are the "brains" of the immune system, coordinating its activity when the body comes under attack. They are also the cells that are attacked by HIV, the devastating virus that causes AIDS and has infected roughly 40 million people worldwide.

Take profits at Elan
Irish Independent - Dublin,Ireland
As hopes for its multiple sclerosis drug Tysabri rose so did the Elan share price. By February 2005 the Elan share price had recovered to €21 and its market ...
See all stories on this topic
Vitamin D fights cancer
Jamaica Gleaner - Kingston,Jamaica
News just in is that women with adequate levels of vitamin D have a higher chance of living cancer-free after early detection and treatment for breast ...
See all stories on this topic

Healthcare In Crisis?
Baby boomers are quickly approaching retirement age, and as they do, there are a number of concerns that need to be addressed, particularly in the area of healthcare. Unfortunately, there appears to be no easy answers to the healthcare problems that baby boomers, and the population in general, will face in the very near future.
The United States faces a medical emergency. Costs of the nation's healthcare system are growing so fast they are out of control. Many employers are dumping escalating healthcare expenses for both employees and their retired workers as fast as they can manage, fearing a loss of competitiveness. Currently, the average American consumes $6,420 worth of healthcare services a year. That's more than $12,200 a year for the average family. It's the most inefficient medical system among industrial nations. US healthcare costs have reached $1.6 trillion a year. That's 15 percent of the nation's economy, up from 5 percent in 1963. Other industrial nations devote less than 10 percent of gross domestic product to healthcare.
Advancements in medical technology and science means that people are living longer. This does not always mean that there is a high quality of life for those that are living longer though. Many of these people who would have died from a medical condition two decades ago can now live for a long time to come. These people often require a great deal of long-term care, whether it is at home or in a long-term care facility.
Those receiving long-term care at home require nurses to help them with their day-to-day tasks. The following is a quote taken directly from the Medicare website (http://www.medicare.gov/LongTermCare/Static/Home.asp)
"Generally, Medicare doesn't pay for long-term care. Medicare pays only for medically necessary skilled nursing facility or home health care. However, you must meet certain conditions for Medicare to pay for these types of care. Most long-term care is to assist people with support services such as activities of daily living like dressing, bathing, and using the bathroom. Medicare doesn't pay for this type of care called "custodial care". Custodial care (non-skilled care) is care that helps you with activities of daily living. It may also include care that most people do for themselves, for example, diabetes monitoring."
There is also a great deal of talk about whether or not Medicare will even be around in the coming decades. Consider the fact that 28% of the population will no longer be contributing to Medicare via taxes, while at the same time that 28% will be using more of the resources.

Thursday, July 24, 2008

Scrap Medicare Fee-For-Service System, Doctor Says

Posted by Jacob Goldstein

They way Medicare pays doctors encourages excessive testing and discourages spending time with patients, a doctor argues today on the New York Times op-ed page.

The fee-for-service system reimburses doctors not only for their time, but also for overhead — which includes the costs of expensive machines used to run tests such as CT scans.

This is why doctors who own their own imaging equipment order far more scans than doctors who refer patients elsewhere for scans, argues the author, Peter B. Bach of Memorial Sloan-Kettering Cancer Center. He writes:

Any first-year business school student can see the profit opportunity here. The cost of a CT scanner is fixed, but a doctor earns fees each time it is used. This means that a scanner becomes highly profitable as soon as it’s paid for.

Patient visits, on the other hand, don’t incur the overhead of fancy machinery and so aren’t big moneymakers in the current system.

Getting rid of this payment system would trim excessive use of expensive tests and encourage docs to spend more time with patients instead, argues Bach, who is a former adviser to Medicare’s top brass.

He suggests paying doctors a fixed amount for each patient, with higher payments for more complex patients to discourage cherry picking. Payment for overhead should be based on the typical costs of tests and treatments for a patient’s condition — similar to how Medicare pays hospitals.

Implementing such a program would be pretty complicated — you could run the risk of giving doctors incentive to under-treat patients, and you’d have to do a good job of setting fees to avoid cherry picking.

Still, it’s worth considering alternatives to the current system. The recent debate in Washington over Medicare payments to doctors is sure to be back next year. And the health-policy gurus we’ve been talking to say financial pressures mean some kind of radical restructuring of the payment system is coming sooner or later.

Photo by Associated Press

http://blogs.wsj.com/health/2008/07/24/scrap-medicare-fee-for-service-system-doctor-says/


Tuesday, July 31, 2007

Why Medical Tourism? A growing 10 Billion Dollar Industry
Medical tourism is the practice of traveling to another country to obtain health care. The provider and patient use informal channels of communication-connection-contract, with less regulatory or legal oversight to assure quality and less formal recourse to reimbursement or redress, if needed. Services typically include elective procedures as well as complex specialized surgeries such as hip and knee joint replacement, cardiac surgery, dental surgery, and cosmetic surgeries.
Due to the high costs of medical treatment and surgery in the United States, the waiting lists in the United Kingdom, Australia and Canada and the lack of high tech medical procedures in many third world countries, medical tourism is expected to blossom into a ten billion dollar business world-wide. Recognizing this trend governments, large corporations, hospitals, and doctors are flooding the medical tourism market with choices, and prices are dropping in many countries world-wide.

The concept of medical tourism is not a new one. The first recorded instance of medical tourism dates back thousands of years to when Greek pilgrims traveled from all over the Mediterranean to the small territory in the Saronic Gulf called Epidauria. This territory was the sanctuary of the healing god Asklepios. Epidauria became the original travel destination for medical tourism.
Medical tourists can come from anywhere in the world, including Europe, the UK, the Middle East, Japan, and the U.S. This is because of their large populations, comparatively high wealth, the high expense of health care or lack of health care options locally, and increasingly high expectations of their populations with respect to health care.
Additionally, patients are finding that insurance either does not cover orthopedic surgery (such as knee/hip replacement) or imposes unreasonable restrictions on the choice of the facility, surgeon, or prosthetics to be used. Medical tourism for knee/hip replacements has emerged as one of the more widely accepted procedures because of the lower cost and minimal difficulties associated with the traveling to/from the surgery. Colombia provides a knee replacement for about $5,000 USD, including all associated fees such as FDA approved prosthetics and hospital stay over expenses. However, many clinics quote prices that are not all inclusive and include only the surgeon fees associated with the procedure
As the number of uninsured Americans grows, medical patients are now becoming consumers of medical care in record numbers. Many of these medical consumers are taking part in medical tourism i.e., people who leave the country primarily for medical treatment.
When a medical consumer searches for a provider, they tend to focus on the credentials of the doctor and forget about other important factors. Possibly the most important other factor is the country where the doctor and hospital are located. The country determines many things about the quality of care you will receive.
A large draw to medical travel is convenience and speed. Countries that operate public health-care systems are often so taxed that it can take considerable time to get non-urgent medical care. The time spent waiting for a procedure such as a hip replacement can be a year or more in Britain and Canada; however, in Singapore, Hong Kong, Thailand, Colombia, Philippines or India, a patient could feasibly have an operation the day after their arrival. In Canada, the number of procedures in 2005 for which people were waiting was 782,936
Factors that have led to the recent increase in popularity of medical travel include the high cost of health care or wait times for procedures in industrialized nations, the ease and affordability of international travel, and improvements in technology and standards of care in many countries of the world.
To understand the phenomenon of medical travel, we can compare the average costs of cosmetic surgeries between the industrialized nations and Latin America countries where medical tourism and cosmetic surgery tourism are becoming popular, such Argentina, Bolivia, Brazil, Costa Rica, Colombia, Philippines, Mexico. Prices quoted in the table below are from offices affiliated with the ministries of health in the U.S., Europe (France, Spain, Switzerland), Argentina, Bolivia, Brazil, Costa Rica, India, and Mexico.
Medical tourism carries some risks that local medical procedures do not. Should complications arise, patients might not be covered by insurance or able to seek compensation via malpractice lawsuits, though it should be noted that malpractice insurance is a considerable portion of the cost in the Western countries such as the US that allow doctors to be sued. The most outspoken critics of medical tourism are U.S. malpractice lawyers who see this emerging trend as a threat to their livelihood. Some countries currently sought after as medical tourism destinations provide some form of legal remedies for medical malpractice. However, this legal avenue is unappealing to the medical tourist. Advocates of medical tourism advise prospective tourists to evaluate the unlikely legal challenges against the benefits of such a trip before undergoing any surgery abroad.
Those involved in medical tourism should seek a hospital in country where government inspections of the hospital are mandated and the standards are high. But just this mandate is not enough. After all the results of the inspections may be known to only a few. Government should also mandate that the results be made public. Such a practice is now law in Germany for German hospitals and other countries in Europe. Wouldn't the medical tourism consumer want to know the results? After all, hospital infection rates vary widely and give the consumer a good idea about how well the hospital is managed.


Aging Could Be A Case Of Specific Genetic Instructions Rather Than Rust - Implying Halting Or Reversing Aging Process May Be Possible One Day
Age may not be rust after all. Specific genetic instructions drive aging in worms, report researchers at the Stanford University School of Medicine. Their discovery contradicts the prevailing theory that aging is a buildup of tissue damage akin to rust, and implies science might eventually halt or even reverse the ravages of age.

Global Stem Cell Forum In China Showcases Cutting Edge Research, Focuses On New Findings For IPS Cells
Over 300 of China's top stem cell biologists and researchers from around the globe shared their latest results and held China's first ever symposium on advanced induced pluripotent stem (iPS) cell research during the just concluded first annual 2008 China Stem Cell Technology Forum at the China Medical City complex in Taizhou, China.

The best places in the world to have cancer00:01 17 July 2008

  • NewScientist.com news service
  • Michael Marshall

Follow the links in the article to explore an interactive map of cancer survival rates

More: Explore our interactive map of cancer survival rates

Women with cancer of the breast, colon or rectum have the best chance of survival if they live in Cuba. Algeria, in contrast, is one of the worst places to be if you have cancer.

Those are just two of many conclusions from a worldwide study comparing survival rates in nearly 2 million cancer patients.

In general, people in North America, Western Europe and other developed countries do better than people from Africa, South America and Eastern Europe.

Within the US, the analysis showed that black people with cancer have a worse chance of survival than white people. For breast cancer, white women had an 84.7% chance of surviving for five years after diagnosis, while for blacks the figure was 70.9%. The black-white disparity was also true of each of the smaller sub-populations within the US that the team were able to analyse. New York was the worst overall city in the US to live in.

Michel Coleman of the London School of Hygiene and Tropical Medicine, and colleagues from around the world, pulled together data from 31 countries across five continents. They looked at cancer of the breast and prostate – in, respectively, women and men only – and of the colorectum in both sexes.

Countries vary in their background mortality rate for many reasons, including crime rates, food availability and water quality. Accordingly, the team calculated "relative survival rates", which attempt to eliminate variation caused by these factors.

Journal reference: The Lancet Oncology (DOI: 10.1016/S1470-2045(08)70179-7)

More: Explore our interactive map of cancer survival rates

Cancer - Learn more about one of the world’s biggest killers in our comprehensive special report.

http://www.newscientist.com/channel/health/dn14331?DCMP=NLC-nletter&nsref=dn14331



Disability Affects Three Out of Every 10 U.S. Adults CME
HYATTSVILLE, Md. -- Nearly 30% of the noninstitutionalized adult U.S. population -- about 62 million people -- have some disability that affects daily activity. full story

http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/tb/10268


Randy Pausch Dies of Pancreatic Cancer 
PITTSBURGH -- Randy Pausch, Ph.D., the Carnegie Mellon professor whose "last lecture" inspired millions with its focus on living his dreams rather than concentrating on his terminal cancer, has died at 47. full story

http://www.medpagetoday.com/HematologyOncology/OtherCancers/tb/10265